Vigabatrin: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Epilepsy and Disorders of Motor Control

Drugs

Volumn 41, Issue 6, 1991, Pages 889-926

  Grant, Susan M ^a   Heel, Rennie C ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; VIGABATRIN;

ADULT; AGED; ATAXIA; CHILD; ELECTROENCEPHALOGRAPHY; EPILEPSY; HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; SPASTICITY; TARDIVE DYSKINESIA;

4-AMINOBUTYRATE TRANSAMINASE; ADULT; AGED; AMINOCAPROIC ACIDS; ANIMAL; ATAXIA; CHILD; DYSKINESIA, DRUG-INDUCED; EPILEPSY; EVOKED POTENTIALS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMAN; INFANT; MUSCLE SPASTICITY; PREGNANCY; PREGNANCY COMPLICATIONS; VIGABATRIN;

EID: 0025788909     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199141060-00007     Document Type: Article

References (160)

1. Neuropathology of a human hippocampus following long-term treatment with vigabatrin: lack of microvacuoles
2. The Epilepsies
3. Microinjections of GABA agonists into the amygdala complex attenuates kindled seizure expression in the rat
4. Effects of vigabatrin on evoked potentials in dogs
5. Pharmacokinetic effects of vigabatrin on cerebrospinal fluid amino acids in humans
6. Case report of surgical brain sample after 2½ years of vigabatrin therapy
7. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients
8. Effect of γ-vinyl GABA on interictal spikes and sharp waves in patients with intractable complex partial seizures
9. γ-Vinyl GABA: comparison of neurochemical and anticonvulsant effects in mice
10. Vigabatrin bei therapieresistenten Epilepsien
11. Correspondence
12. Vigabatrin and behaviour disturbances
13. The relationship between GABA concentrations in brain and cerebrospinal fluid
14. The effect of vigabatrin on brain and platelet GABA-transaminase activities
15. Anticonvulsarit action of intranigral γ-vinyl-GABA: role of noradrenergic neurotransmission
16. A. controlled study of oral vigabatrin (γ-vinyl GABA) in patients with cerebellar ataxia
17. Vigabatrin and psychosis
18. Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up
19. A multicentre long-term study of vigabatrin (VGB). Abstract 155S
20. The neuropathology of vigabatrin
21. A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats
22. Double-blind study of oral γ-vinyl GABA in the treatment of dystonia
23. Bidirectional effects of β-carbolines in reflex epilepsy
24. Vigabatrin in infantile spasms
25. Magnetic resonance imaging in epileptic children treated with γ-vinyl-GABA (vigabatrin)
26. Vigabatrin in complex partial seizures: a long-term study
27. Anorectic potency of inhibiting GABA transaminase in brain: studies of hypothalamic, dietary and genetic obesities
28. Effect of vigabatrin (gamma-vinyl-GABA) on visual, brainstem auditory and somatosensory evoked potentials in epileptic patients
29. Effects of vigabatrin on evoked potentials in epileptic patients
30. Long-term evaluation of vigabatrin (gamma vinyl GABA) in epilepsy
31. Vigabatrin and behaviour disturbances
32. GABA-ergic analgesia — an overview
33. Effect of gamma-vinyl GABA in Friedreich’s ataxia
34. Cellular mechanisms of epilepsy and potential new treatment strategies
35. Localization in the brain of the inhibition by GABA of luteinizing hormone release that follows orchidectomy in rats
36. Blockade of the LH surge and ovulation by GABA-T inhibitory drugs that increase brain GABA levels in rats
37. Effect of food on the absorption of vigabatrin
38. GABA in epilepsy. The pharmacologic basis
39. Tardive dyskinesia. Pathophysiological mechanisms and clinical trials
40. A comparison of GABAergic influences on the analgesic responses to morphine and pentazocine
41. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor
42. Neuropathology of vigabatrin
43. Experimental studies and controlled clinical testing of valproate and vigabatrin
44. γ-Vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy
45. Effects of valproate, vigabatrin and aminooxyacetic acid on release of endogenous and exogenous GABA from cultured neurons
46. Experimental studies of the influence of vigabatrin on the GABA system
47. Assay of γ-vinyl-γ-aminobutyric acid (4-amino-hex-5-enoic acid) in plasma and urine by automatic amino acid analysis
48. Cerebrospinal fluid GABA as an index of brain GABA activity
49. Increased gamma-aminobutyric acid (GABA), homocarnosine and β-alanine in cerebrospinal fluid of patients treated with γ-vinyl GABA (4-amino-hex-5-enoic acid)
50. Pharmacokinetics of vigabatrin: implications of creatinine clearance
51. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer
52. Inhibitory and excitatory amino acids in CSF of patients suffering from complex partial seizures during chronic treatment with γ-vinyl GABA (vigabatrin)
53. Administration of vigabatrin (γ-vinyl-γ-aminobutyric acid) affects the levels of both inhibitory and excitatory amino acids in rat cerebrospinal fluid
54. Evoked potential monitoring of vigabatrin patients
55. Effects of gamma-vinyl-GABA on the human electroencephalogram
56. Effect of gamma-vinyl GABA on human pattern evoked visual potentials
57. Minireview. Gamma-vinyl GABA
58. Synthesis, brain uptake, and pharmacological properties of a glyceryl lipid containing GABA and the GABA-T inhibitor γ-vinyl-GABA
59. Micro-vacuolation in rat brains after long term administration of GABA-transaminase inhibitors. Comparison of effects of ethanolamine-O-sulphate and vigabatrin
60. Experimental febrile convulsions in epileptic chickens: the anticonvulsant effect of elevated γ-aminobutyric acid concentrations
61. Correspondence
62. Pharmacology of neural pathways affecting CRH secretion
63. Hepatic encephalopathy: new light on an old problem
64. γ-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice
65. Platelet GABA-transaminase activity in epileptic patients on vigabatrin therapy
66. Effect of gamma-vinyl-GABA in tardive dyskinesia
67. Essai thérapeutique du γ-vinyl GABA, un inhibiteur de la GABA-transaminase, dans les dyskinésies tardives induites par les neuroleptiques
68. Effets du gamma-vinyl GABA per osdans cinq cas de schizophrénie hébéphréno-catatonique
69. Blockade of pro-oestrus LH surge and ovulation by GABA increase in the rat locus coeruleus
70. Differential effect of gamma-vinyl GABA and valproate on GABA-transaminase from cultured neurones and astrocytes
71. Effects of long-term vigabatrin on somatosensory-evoked potentials in epileptic patients
72. 4-Amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain
73. Potentiation of γ-vinyl GABA (vigabatrin) effects by glycine
74. Vigabatrin in the treatment of epilepsy in children
75. Alterations of GABA-mediated synaptic transmission in human epilepsy
76. Doubles-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy
77. Effect of inhibitors of GABA transaminase on the synthesis, binding, uptake, and metabolism of GABA
78. Effect of inhibitors of GABA aminotransferase on the metabolism of GABA in brain tissue and synäptosomal fractions
79. One to three day dose intervals during subchronic treatment of epileptic gerbils with γ-vinyl GABA: anticonvulsant efficacy and alterations in regional brain GABA levels
80. Anticonvulsant and proconvulsant effects of inhibitors of GABA degradation in the amygdala-kindling model
81. Vigabatrin in the treatment of childhood epilepsies: a single-blind placebo-controlled study
82. Recent advances in the treatment of cerebellar ataxias
83. Diazepam antagonizes GABAmimetics in rats with spontaneous petit mal-like epilepsy
84. Effect of vigabatrin on epilepsy in mentally retarded patients: a 7-month follow-up study
85. GABAergic mechanisms in the pathogenesis and treatment of epilepsy
86. Anatomy, physiology, and pathology of epilepsy
87. Blockade of epileptic responses in the photosensitive baboon, Papio papio, by two irreversible inhibitors of GABA-transaminase, γ-acetylenic GABA (4-amino-hex-5-ynoic acid) and γ-vinyl GABA (4-amino-hex-5-enoic acid)
88. Electrophysiologic effects of γ-vinyl GABA and carbamazepine
89. Suicide inhibitors of GABA transaminase
90. Response to vigabatrin in relation to seizure type
91. Efficacia a lungo termine del Vigabatrin nell’epilessia farmacoresistente
92. Effects of GABAergic drugs in vivo on high-affinity choline uptake in vitro in mouse hippocampal synaptosomes
93. Functional anatomy of pentylenetetrazol and electroshock seizures in the rat brainstem
94. A profile of vigabatrin
95. Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy
96. Immunocyto-chemical evidence that vigabatrin in rats causes GABA accumulation in glial cells of the retina
97. Development of tolerance to the effects of vigabatrin (γ-vinyl-GABA) on GABA release from rat cerebral cortex, spinal cord and retina
98. Graded increases in brain GABA: differential effects on feeding and other behaviours in rats
99. GABA modulation of monoaminergic systems in the brain
100. Total GABA and homocarnosine in CSF as indices of brain GABA concentrations
101. The pharmacology of GABA-transaminase inhibitors
102. Neuropathological findings in 5 patients with vigabatrin treatment
103. Regulation of transmitter γ-aminobutyric acid (GABA) synthesis and metabolism illustrated by the effect of γ-vinyl GABA and hypoglycemia
104. Vigabatrin: no microvacuoles in a human brain
105. Long-term study of gamma-vinyl GABA in the treatment of epilepsy
106. CSF soluble proteins and vigabatrin
107. Somatostatin, β-endorphin, and prolactin levels in human cerebrospinal fluid during the γ-vinyl-GABA treatment of patients with complex partial epilepsy
108. Levels of total γ-aminobutyric acid (GABA), free GABA and homocarnosine in cerebrospinal fluid of epileptic patients before and during γ-vinyl-GABA (vigabatrin) treatment
109. Evaluation in man
110. Electrophysiologic effects of acute and chronic gamma-vinyl-GABA on GABA-mediated inhibition in the rat hippocampus
111. Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy
112. Long term follow-up of patients treated with vigabatrin for refractory epilepsy
113. Etude en double aveugle contre placebo en permutations croisées du vigabatrin dans l’épilepsie de l’adulte résistant a la thérapeutique
114. Pharmacokinetics of the individual enantiomers of vigabatrin (γ-vinyl GABA) in epileptic children
115. A controlled trial of gamma-vinyl-GABA (vigabatrin) in drug-resistant epilepsy
116. The controlled clinical trial in epilepsy
117. Effect of gamma-vinyl GABA treatment on cholinergic and aminergic neurotransmission and on cyclic nucleotides in human complex partial epilepsy — a CSF study
118. Specificity of vigabatrin for the GABAergic system in human epilepsy
119. Inhibition of the enzyme, GABA-aminotransferase in human platelets by vigabatrin, a potential antiepileptic drug
120. A comparison of the acute effect of single doses of vigabatrin and sodium valproate on photosensitivity in epileptic patients
121. Double-blind study of γ-vinyl GABA in patients with refractory epilepsy
122. Interaction between vigabatrin and phenytoin
123. Vigabatrin: rational treatment for chronic epilepsy
124. Vigabatrin and behaviour disturbance
125. Vigabatrin and behaviour disturbances
126. Psychophysiological and psychometric studies after manipulating the GABA system by vigabatrin, a GABA-transaminase inhibitor
127. Vigabatrin and behaviour disturbances
128. Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy
129. Proline and proline derivatives as anticonvulsants
130. Vigabatrin
131. Clinical pharmacology of vigabatrin
132. Biochemical and pharmacological similarities and differences among four irreversible enzyme-activated GABA-T inhibitors
133. Biochemical and clinical effects of γ-vinyl GABA in patients with epilepsy
134. Attempts to correlate alterations in brain GABA metabolism by GABA-T inhibitors with their anticonvulsant effects
135. Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of γ-acetylenic GABA and γ-vinyl GABA, two irreversible GABA-T inhibitors
136. Stereoselective uptake of the GABA-transaminase inhibitors gamma-vinyl GABA and gamma-acetylenic GABA into neurons and astrocytes
137. Vigabatrin-induced intramyelinic edema I: effects on visual and somatosensory evoked potentials in dogs. Abstract 760S
138. Gamma-vinyl GABA treatment of Huntington’s disease
139. Is there a place for placebo controlled trials of antiepileptic drugs?
140. Double-blind dose reduction study of vigabatrin in complex partial epilepsy
141. Vigabatrin in drug-resistant partial epilepsy: a 5-year follow-up study
142. Quantitative analysis of vigabatrin in plasma and urine by reversed-phase high-performance liquid chromatography
143. Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders
144. γ-Vinyl GABA in endopiriform area suppresses kindled amygdala seizures
145. GABA agonist treatment improves tardive dyskinesia
146. GABAmimetic treatments for tardive dyskinesia: efficacy and mechanism
147. Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study
148. Vigabatrin in the treatment of epilepsy: a long-term follow-up study
149. Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy
150. Suppression of methionine sulfoximine seizures by intranigral γ-vinyl GABA injection
151. Part three. The psychoses of epilepsy
152. Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or γ-vinyl-GABA into the substantia nigra
153. Vigabatrin-induced intramyelinic edema II: effects on MRI in dogs. Abstract 761S